Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

25. Juni 2019 14:01 ET | Quelle: ImmusanT, Inc.

ImmusanT Discontinues Phase 2 Clinical Trial for Nexvax2® in Patients With Celiac Disease

CAMBRIDGE, Mass., June 25, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
29. Mai 2019 10:17 ET | Quelle: ImmusanT, Inc.

ImmusanT to Present at the Jefferies 2019 Healthcare Conference

CAMBRIDGE, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
21. Mai 2019 12:12 ET | Quelle: ImmusanT, Inc.

ImmusanT Presents Early Evidence Supporting its Lead Therapeutic Vaccine Candidate During the Digestive Disease Week Annual Conference 2019

CAMBRIDGE, Mass., May 21, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
16. Mai 2019 10:35 ET | Quelle: ImmusanT, Inc.

ImmusanT to Present New Findings on Celiac Disease and Lead Therapeutic Candidate During the Digestive Disease Week Annual Conference 2019

CAMBRIDGE, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
21. März 2019 13:00 ET | Quelle: ImmusanT, Inc.

ImmusanT to Present and Participate in Multiple Upcoming Industry and Scientific Conferences

ImmusanT CEO Leslie Williams to speak on panel during the MassBio Annual “The State of Possible Conference” ImmusanT CSO Dr. Bob Anderson to present on Nexvax2 at the 2nd Antigen Specific Immune...
06. März 2019 08:00 ET | Quelle: ImmusanT, Inc.

ImmusanT to Provide Corporate Overview at the Cowen & Company 39th Annual Health Care Conference

CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical-stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
03. Januar 2019 09:47 ET | Quelle: ImmusanT, Inc.

ImmusanT Expands Senior Management Team with Appointment of Thomas A. Shea as Chief Financial Officer

CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical-stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
02. Januar 2019 10:17 ET | Quelle: ImmusanT, Inc.

ImmusanT Secures Fast-Track Designation for Lead Therapeutic Vaccine Candidate Nexvax2 for Patients with Celiac Disease (CeD)

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical-stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
07. Dezember 2018 12:53 ET | Quelle: ImmusanT, Inc.

ImmusanT Chief Scientific Officer Robert Anderson, Ph.D. to Participate as a Featured Speaker During the Antigen-Specific Immune Tolerance Europe Conference 2018

CAMBRIDGE, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
20. November 2018 09:30 ET | Quelle: ImmusanT, Inc.

ImmusanT CEO Leslie Williams to Present at Multiple Life Sciences Events to Share Company’s Leadership Position in the Industry and Successful Growth Strategy

CAMBRIDGE, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...

Nächste Seite